ArticleTrends in molecular medicine2010
Nanotechnology for synthetic high-density lipoproteins.
Article in Trends in molecular medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 32 citations in OpenAlex.
- Keratinocyte SR-B1 expression and targeting in cytokine-driven skin inflammation.Communications medicine · 2025Article
- Article
- Synthetic high-density lipoprotein nanoparticles: Good things in small packages.The ocular surface · 2021Review
- Structure and intermolecular interactions in spheroidal high-density lipoprotein subpopulations.Journal of structural biology: X · 2021Article
- Artificial High Density Lipoprotein Nanoparticles in Cardiovascular Research.Molecules (Basel, Switzerland) · 2019Review
- Nanoparticle systems for cancer vaccine.Nanomedicine (London, England) · 2019Review
- Nitric Oxide-Delivering High-Density Lipoprotein-like Nanoparticles as a Biomimetic Nanotherapy for Vascular Diseases.ACS applied materials & interfaces · 2018Article
- Detection and treatment of atherosclerosis using nanoparticles.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2017Review
- Pathways for Modulating Exosome Lipids Identified By High-Density Lipoprotein-Like Nanoparticle Binding to Scavenger Receptor Type B-1.Scientific reports · 2016Article
- Mimicry of high-density lipoprotein: functional peptide-lipid nanoparticles based on multivalent peptide constructs.Journal of the American Chemical Society · 2013Article
- Biomimetic, synthetic HDL nanostructures for lymphoma.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- More effective nanomedicines through particle design.Small (Weinheim an der Bergstrasse, Germany) · 2011Review
- Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery.Nano letters · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Atherosclerosis is the disease mechanism responsible for coronary heart disease (CHD), the leading cause of death worldwide. One strategy to combat atherosclerosis is to increase the amount of circulating high-density lipoproteins (HDL), which transport cholesterol from peripheral tissues to the liver for excretion. The process, known as reverse cholesterol transport, is thought to be one of the main reasons for the significant inverse correlation observed between HDL blood levels and the development of CHD. This article highlights the most common strategies for treating atherosclerosis using HDL. We further detail potential treatment opportunities that utilize nanotechnology to increase the amount of HDL in circulation. The synthesis of biomimetic HDL nanostructures that replicate the chemical and physical properties of natural HDL provides novel materials for investigating the structure-function relationships of HDL and for potential new therapeutics to combat CHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.